Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Biogen Idec

Tysabri sales fuel growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 1Q10

1Q Revenues: $1.1 billion (+7%)

1Q Earnings: $220 million (-11%)

Comments: Tysabri sales rose 32% to $219 million in the quarter, while Avonex sales were up 7% to $593 million. Rituxan revenues dropped 9% to $255 million. BI wrote down $14 million from its investment in AVEO Pharmaceuticals, and another $13 million in expanded Medicaid rebates.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters